Isotechnika Enrols First Patient in Phase IIb Kidney Transplant Trial

Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announcedtoday that the Company enrolled its first patient in a NorthAmerican Phase IIb kidney transplant trial for its leadimmunosuppressive drug, ISA247, on January 4, 2006.

The trial will be performed at thirty-four centers across NorthAmerica , including twenty-nine centers in the United States and fivecenters in Canada. A total of 332 de novo (newly transplanted)kidney transplant patients will be enrolled in this trial. Patientswill be placed into one of four separate treatment groups; threedifferent dose groups of ISA247 (0 .4 mg/kg, 0.6 mg/kg, and 0.8 mg/kgtwice daily) compared with the fourth group, a tacrolimus (0.05mg/kg twice daily) control arm. Patients in all four treatmentgroups will have their doses adjusted in order to achievepre-defined blood levels of either ISA247 or tacrolimus. All patientswill receive oral treatment of drug (ISA247 or tacrolimus) over asix month period along with other standard immunosuppressivetherapies used following transplantation.

The primary endpoint of the trial is defined as non-inferiority inbiopsy proven acute rejection (BPAR) episodes in patients receivingISA247 for six months as compared to the tacrolimus control.Additionally, kidney function and other laboratory parameters suchas hypertension, hyperlipidemia and new onset diabetes mellitus willbe monitored for the duration of the trial. The overall goal of thetrial is to find the most appropriate dose that will result inefficacy (lack of rejection) with minimal side effects that aretypically seen with other calcineurin inhibitors such ascyclosporine and tacrolimus.

"Enrolling our first patient in a timely manner speaks to ourongoing commitment to development timelines," stated Dr. RandallYatscoff, Isotechnika's President & CEO. "We are excited to moveISA247 forward in the area of transplantation as well as for thetreatment of psoriasis. We look forward to providing future progressreports to the investment and scientific communities in both ofthese areas."

About Isotechnika

Isotechnika Inc. is an international biopharmaceutical companyheadquartered in Edmonton, Alberta, Canada. Drawing upon itsexpertise in medicinal chemistry and immunology, the Company isfocused on the discovery and development of novel immunosuppressivetherapeutics that are safer than currently available treatments. Itsentrepreneurial management and world- class team of scientists arebuilding a pipeline of immunosuppressive drug candidates fortreatment of autoimmune diseases and for use in the prevention oforgan rejection in transplantation. Isotechnika looks to become theleader in development of immunosuppressant therapies.

Isotechnika's lead compound, ISA247 is an immunosuppressantcurrently in an extension protocol of a Canadian Phase III humanclinical trial for the treatment of moderate to severe psoriasis. Inaddition, ISA247 has successfully completed a Phase IIa trial forkidney transplantation. The Company also has an additionalimmunosuppressive compound in its drug pipeline, TAFA93 which is inPhase I.

Isotechnika Inc. is a publicly traded company on the Toronto StockExchange under the symbol ISA. More information on Isotechnika can befound at www.isotechnika.com.


Isotechnika Inc. has a collaboration agreement with Hoffman LaRoche which licensed the worldwide rights to develop andcommercialize Isotechnika's novel molecule ISA247 for all transplantindications.

In addition, the Company has an exclusive worldwide licensingagreement with Atrium Medical Corporation for the use of ISA247 andTAFA93 specifically with drug eluting devices for the non-systemictreatment of vascular, cardiovascular, target vessel and tissuedisorders.

Forward-Looking Statements

This press release may contain forward-looking statements. Forwardlooking statements, including the Company's belief as to thepotential of its products, the Company's expectations regarding theissuance of additional patents and the Company's ability to protectits intellectual property, involve known and unknown risks anduncertainties, which could cause the Company's actual results todiffer materially from those in the forward looking statements. Suchrisks and uncertainties include, among others, the availability offunds and resources to pursue research and development projects, theability to economically manufacture its products, the potential ofits products, the success and timely completion of clinical studiesand trials, the Company's ability to successfully commercialize itsproducts, the ability of the Company to defend its patents frominfringement by third parties, and the risk that the Company'spatents may be subsequently shown to be invalid or infringe thepatents of others. Investors should consult the Company's quarterlyand annual filings with the Canadian commissions for additionalinformation on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing unduereliance on forward-looking statements.

ots Originaltext: Isotechnika Inc.Im Internet recherchierbar: http://www.presseportal.de

Contact:For further information: Dr. Randall Yatscoff, President & CEO, Isotechnika Inc., Phone: +1-(780)-487-1600 Ext. 246, Fax: +1-(780)-484-4105, Email: ryatscoff@isotechnika.com; Stephanie Gillis-Paulgaard, Director, Corporate Communications, Isotechnika Inc., Phone: +1-(780)-909-4661, Fax: +1-(780)-484-4105, E-mail: sgillis-paulgaard@isotechnika.com; To request a free copy of this organization's annual report, please go to http://www.newswire.ca andclick on Tools for Investors.

Isotechnika Inc.

Zurück zur Übersiche Medizin-Nachrichten

Preisvergleich Medikamente
Medikament oder PZN:   
In Zusammenarbeit mit Medizinfuchs


Isotechnika Enrols First Patient in Phase IIb Kidney Transplant Trial